Iridex Corp was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, the Company changed its name to IRIDEX Corporation and reincorporated in Delaware. It is a provider of therapeutic based laser systems, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. Its ophthalmology products consist of laser console, delivery devices and consumable instrumentation including laser probes, and are used in the treatment of serious eye diseases, including the three causes of irreversible blindness: diabetic retinopathy, glaucoma and age-related macular degeneration. In addition, its ophthalmology products are often used in vitrectomy procedures which are generally performed in the operating room and require a consumable single use intraocular laser probe to deliver the light to the back of the eye. Its laser systems consist of IQ products which include IQ 532, IQ 577 and IQ 810 laser photocoagulation systems; and its OcuLight products including OcuLight TX, OcuLight Symphony, OcuLight SL, OcuLight SLx, OcuLight GL and OcuLight GLx laser photocoagulation systems. The Company utilizes a systems approach to product design. Each system includes a console, which generates the laser energy, and a number of interchangeable peripheral delivery devices for use in specific clinical applications. Customers include research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. The Company sells and markets its products in the United States predominantly through its direct sales force and internationally through independent distributors. The Company has been issued 28 United States patents and 14 foreign patents. The medical devices marketed and manufactured by the company are subject to extensive regulation by numerous governmental authorities, including federal, state, and foreign governmental agencies.